SB 913

Drug Profile

SB 913

Alternative Names: SB-913

Latest Information Update: 11 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sangamo Therapeutics
  • Class Gene therapies; Zinc finger DNA binding proteins
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mucopolysaccharidosis II
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Mucopolysaccharidosis II

Most Recent Events

  • 07 Dec 2017 The Committee for Orphan Medicinal Products issues a positive opinion on the application for orphan medicinal product designation for SB 913 for Mucopolysaccharidosis Type II
  • 13 Jul 2017 SB 913 receives Fast Track designation for Mucopolysaccharidosis II [IV,Infusion] in USA
  • 04 May 2017 SB 913 receives Rare Paediatric Disease designation for Mucopolysaccharidosis II in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top